681 related articles for article (PubMed ID: 31088535)
1. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
[TBL] [Abstract][Full Text] [Related]
3. Glutamate-Weighted Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Detects Glutaminase Inhibition in a Mouse Model of Triple-Negative Breast Cancer.
Zhou R; Bagga P; Nath K; Hariharan H; Mankoff DA; Reddy R
Cancer Res; 2018 Oct; 78(19):5521-5526. PubMed ID: 30072394
[TBL] [Abstract][Full Text] [Related]
4. 13C high-resolution-magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns.
Grinde MT; Moestue SA; Borgan E; Risa Ø; Engebraaten O; Gribbestad IS
NMR Biomed; 2011 Dec; 24(10):1243-52. PubMed ID: 21462378
[TBL] [Abstract][Full Text] [Related]
5. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
Singleton DC; Dechaume AL; Murray PM; Katt WP; Baguley BC; Leung EY
BMC Cancer; 2020 May; 20(1):470. PubMed ID: 32450839
[TBL] [Abstract][Full Text] [Related]
6. [
Zhou R; Pantel AR; Li S; Lieberman BP; Ploessl K; Choi H; Blankemeyer E; Lee H; Kung HF; Mach RH; Mankoff DA
Cancer Res; 2017 Mar; 77(6):1476-1484. PubMed ID: 28202527
[TBL] [Abstract][Full Text] [Related]
7. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice.
Boysen G; Jamshidi-Parsian A; Davis MA; Siegel ER; Simecka CM; Kore RA; Dings RPM; Griffin RJ
Int J Radiat Biol; 2019 Apr; 95(4):436-442. PubMed ID: 30557074
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.
Reis LMD; Adamoski D; Ornitz Oliveira Souza R; Rodrigues Ascenção CF; Sousa de Oliveira KR; Corrêa-da-Silva F; Malta de Sá Patroni F; Meira Dias M; Consonni SR; Mendes de Moraes-Vieira PM; Silber AM; Dias SMG
J Biol Chem; 2019 Jun; 294(24):9342-9357. PubMed ID: 31040181
[TBL] [Abstract][Full Text] [Related]
9. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
Lampa M; Arlt H; He T; Ospina B; Reeves J; Zhang B; Murtie J; Deng G; Barberis C; Hoffmann D; Cheng H; Pollard J; Winter C; Richon V; Garcia-Escheverria C; Adrian F; Wiederschain D; Srinivasan L
PLoS One; 2017; 12(9):e0185092. PubMed ID: 28950000
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
Kim E; Tunset HM; Cebulla J; Vettukattil R; Helgesen H; Feuerherm AJ; Engebråten O; Mælandsmo GM; Johansen B; Moestue SA
BMC Cancer; 2016 Mar; 16():191. PubMed ID: 26951085
[TBL] [Abstract][Full Text] [Related]
11. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models.
Moestue SA; Borgan E; Huuse EM; Lindholm EM; Sitter B; Børresen-Dale AL; Engebraaten O; Maelandsmo GM; Gribbestad IS
BMC Cancer; 2010 Aug; 10():433. PubMed ID: 20716336
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer Xenografts.
Euceda LR; Hill DK; Stokke E; Hatem R; El Botty R; Bièche I; Marangoni E; Bathen TF; Moestue SA
J Proteome Res; 2017 May; 16(5):1868-1879. PubMed ID: 28290700
[TBL] [Abstract][Full Text] [Related]
13. Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate.
Korangath P; Teo WW; Sadik H; Han L; Mori N; Huijts CM; Wildes F; Bharti S; Zhang Z; Santa-Maria CA; Tsai H; Dang CV; Stearns V; Bhujwalla ZM; Sukumar S
Clin Cancer Res; 2015 Jul; 21(14):3263-73. PubMed ID: 25813021
[TBL] [Abstract][Full Text] [Related]
14. Metabolic characterization of triple negative breast cancer.
Cao MD; Lamichhane S; Lundgren S; Bofin A; Fjøsne H; Giskeødegård GF; Bathen TF
BMC Cancer; 2014 Dec; 14():941. PubMed ID: 25495193
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
[TBL] [Abstract][Full Text] [Related]
16. MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
Craze ML; Cheung H; Jewa N; Coimbra NDM; Soria D; El-Ansari R; Aleskandarany MA; Wai Cheng K; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Br J Cancer; 2018 Jan; 118(2):258-265. PubMed ID: 29169183
[TBL] [Abstract][Full Text] [Related]
17. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
Gregory MA; Nemkov T; Reisz JA; Zaberezhnyy V; Hansen KC; D'Alessandro A; DeGregori J
Exp Hematol; 2018 Feb; 58():52-58. PubMed ID: 28947392
[TBL] [Abstract][Full Text] [Related]
18.
Zhou R; Choi H; Cao J; Pantel A; Gupta M; Lee HS; Mankoff D
J Nucl Med; 2023 Jan; 64(1):131-136. PubMed ID: 35772960
[TBL] [Abstract][Full Text] [Related]
19. GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy.
Mukha A; Kahya U; Linge A; Chen O; Löck S; Lukiyanchuk V; Richter S; Alves TC; Peitzsch M; Telychko V; Skvortsov S; Negro G; Aschenbrenner B; Skvortsova II; Mirtschink P; Lohaus F; Hölscher T; Neubauer H; Rivandi M; Labitzky V; Lange T; Franken A; Behrens B; Stoecklein NH; Toma M; Sommer U; Zschaeck S; Rehm M; Eisenhofer G; Schwager C; Abdollahi A; Groeben C; Kunz-Schughart LA; Baretton GB; Baumann M; Krause M; Peitzsch C; Dubrovska A
Theranostics; 2021; 11(16):7844-7868. PubMed ID: 34335968
[TBL] [Abstract][Full Text] [Related]
20. Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers.
Rashmi R; Jayachandran K; Zhang J; Menon V; Muhammad N; Zahner M; Ruiz F; Zhang S; Cho K; Wang Y; Huang X; Huang Y; McCormick ML; Rogers BE; Spitz DR; Patti GJ; Schwarz JK
Mol Cancer Ther; 2020 Dec; 19(12):2465-2475. PubMed ID: 33087507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
